Emergent BioSolutions Inc.

NYSE:EBS

Biotechnology

Healthcare
$5.50 -2.58%

-$0.21 today

Market cap
$282.78M
Beta
2.33
P/E (TTM)
-47.9
EPS (TTM)
-$0.17
52W Low $5.62High $14.06

Volume 0.82M

Average 0.78M

EBS Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Emergent BioSolutions Inc.NYSE: EBS

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of $46.6M fell 11.6% year over year, ahead of the -32.3% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 8.8% from the prior quarter. Over 3 fiscal years it compounded at -18.1% a year.

Context

  • Selling, general & admin amounted to 25.1% of revenue in FY2025, down 3.5 pp from a year earlier.
  • Selling, general & admin increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 2 analysts of $178.22M (-4.5%) for the fiscal year ending Dec 2026, a step up from the -37.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$46.6M-8.8% QoQ
Last fiscal yearDec 2025
$186.6M-37.5% YoY
LTMMar 2026
$180.5M-32.3% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-11.6%+11.2%+22.7 pp
1 year-37.5%-4.5%+33.0 pp
3-year CAGR-18.1%-2.5%+15.6 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
186.6M USD
Year-over-year change
-37.5%
4-year CAGR
-14.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How EBS compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -32.3% is the lowest of 11, against a peer median of +7.0%.
  • Selling, general & admin amounts to 26.7% of revenue for EBS, versus a peer median of 62.1%.
EBS Competitors
Selling, General & Admin for EBS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SIGASIGA Technologies, Inc.LTM Mar 2026$4.67T USD+20374087.6%-55.3%4982813.7%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$318.91M USD+8.2%+4.8%62.1%
SNDLSNDL Inc.LTM Mar 2026CA$210.35M CAD-3.8%+10.0%22.4%
EBSEmergent BioSolutions Inc.LTM Mar 2026$180.5M USD-32.3%-18.1%26.7%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$165.91M USD+1.1%+15.0%39.7%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$118.84M USD+5.8%+1.0%39.6%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$71.75M USD+22.5%+14.7%142.7%
CMPSCOMPASS Pathways plcLTM Mar 2026$58.26M USD-9.3%+10.1%—
PRTAProthena Corporation plcLTM Mar 2026$54.46M USD-19.1%+6.0%94.0%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$25.39M USD+44.8%-5.3%—
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$10.49M USD+24.0%+4.5%—
Peer median (excluding EBS) —+7.0%+5.4%62.1%

Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.77B1.12B1.05B1.04B742.9M
Cost of Revenue980.4M644.5M689.3M668.2M392.3M
Gross Profit793.2M473M360M375.4M350.6M
Gross Margin44.7%42.3%34.3%36.0%47.2%
Research & Development235.2M188.3M111.4M70.7M53.8M
Selling, General & Admin348.7M339.5M356.7M298.7M186.6M
Operating Expenses451.8M643M1.09B484.1M240.4M
Depreciation & Amortization118.2M125M121.1M105.6M98.3M
EBITDA504.2M15.7M(47M)53.4M240.4M
EBITDA Margin28.4%1.4%-4.5%5.1%32.4%
Operating Income341.4M(170M)(726.4M)(108.7M)110.2M
Operating Margin19.2%-15.2%-69.2%-10.4%14.8%
Interest Income00000
Interest Expense34.5M37.3M87.9M71M59.3M
Other Income / Expenses(38.2M)(49M)(4.8M)(34.2M)(27.4M)
Income Before Tax303.2M(219M)(731.2M)(142.9M)82.8M
Pre-Tax Margin17.1%-19.6%-69.7%-13.7%11.1%
Income Tax Expense83.7M(7.4M)29.3M47.7M30.2M
Net Income219.5M(211.6M)(760.5M)(190.6M)52.6M
Net Margin12.4%-18.9%-72.5%-18.3%7.1%
EPS (Basic)4.10(4.22)(14.85)(3.60)0.98
EPS (Diluted)4.06(4.22)(14.85)(3.60)0.93
Weighted Avg Shares53.5M50.1M51.2M53M53.5M
Weighted Avg Shares (Diluted)54.1M50.1M51.2M53M56.7M

Emergent BioSolutions Inc.

NYSE:EBS

Intrinsic Alpha fair value

Locked

Current Price

$5.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.